Current Report Filing (8-k)
06 10월 2017 - 7:04PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
______________
FORM 8-K
______________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
t
he
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported):
October
5, 2017
USANA HEALTH
SCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Utah
(State
or other jurisdiction of incorporation)
001-35024
|
|
87-0500306
|
(Commission File No.)
|
|
(IRS Employer Identification
|
|
|
Number)
|
3838 West Parkway Boulevard
Salt Lake City, Utah 84120
|
(Address
of principal executive offices,
Zip
Code)
|
Registrant’s
telephone number, including area code:
(801)
954-7100
|
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
Emerging Growth Company
⃞
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with
any new or revised financialaccounting standards provided pursuant to
Section 13(a) of the Exchange Act.
⃞
Item 5.02, Departure of Directors or Principal Officers; Election of
Directors; Appointment of Principal Officers
Effective as of October 5, 2017, the Board of Directors of USANA Health
Sciences, Inc. (the “Company”) acted unanimously to appoint Mr. J. Scott
Nixon as an additional director of the Company, for an initial term
expiring at the Company’s 2018 Annual Meeting of Shareholders. Mr. Nixon
has not been appointed to any Committees of the Board of Directors at
this time.
Mr. Nixon, a certified public accountant, retired in 2015 as a partner
with PricewaterhouseCoopers LLP (PwC) where he spent over 31 years in
various roles including Office Managing Partner and engagement partner
over public and private companies in many industries. His career
involved providing audit and business advisory services. Mr. Nixon was
involved in numerous complex filings with the Securities and Exchange
Commission on behalf of his clients. In 2007, Mr. Nixon returned from a
four-year assignment in São Paulo, Brazil where he represented various
interests of the PwC global firm to the 18-member firms in South and
Central America, and led the implementation and compliance of the
Sarbanes-Oxley requirements in those countries. Mr. Nixon has served as
a member of the Board of Directors of ProLung, Inc. since November 2016.
He also serves on several boards of directors for private and non-profit
companies, including Deseret Trust Company as a member of the Audit and
Executive Committees since 2015 and Utah State University Board of
Trustees, as Chairman of the Audit Committee since 2011. Mr. Nixon is
currently a Trustee, Vice Chairman and a member of the Executive
Committee of MountainWest Capital Network and is a National Association
of Corporate Directors (NACD) Governance Fellow. He holds both a BA and
Master of Accounting from Utah State University.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1
Press
release issued by USANA Health Sciences, Inc. dated October 5, 2017
(furnished herewith).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
USANA HEALTH SCIENCES, INC.
|
|
|
|
|
|
|
|
|
By:
/s/ Douglas Hekking
|
|
|
|
|
|
G. Douglas Hekking, Chief Financial Officer
|
|
|
|
|
|
|
Date:
|
October 5, 2017
|
|
USANA Health Sciences (NYSE:USNA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
USANA Health Sciences (NYSE:USNA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024